^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TLY012

    i
    Other names: TLY012, TLY 012, pegylated recombinant human TRAIL
    Associations

    News

    Trials
    Company:
    D&D Pharmatech
    Drug class:
    TRAIL R2 agonist
    Related drugs:
    Associations

    News

    Trials
    almost3years
    Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. (PubMed, Cancer Biol Ther)
    Taken together, the preclinical efficacy of ONC201 and TLY012 represents a novel therapeutic option for further testing in pancreatic cancer patients. This combination showed marked efficacy in tumor cells that are both sensitive and resistant to the pro-apoptotic effects of ONC201, providing rationale to further investigate the combination of ONC201 plus TLY012 in patients with pancreatic cancer.
    Preclinical • Journal
    |
    BCL2L1 (BCL2-like 1) • TNFA (Tumor Necrosis Factor-Alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • XIAP (X-Linked Inhibitor Of Apoptosis) • ATF4 (Activating Transcription Factor 4) • CFLAR (CASP8 and FADD-like apoptosis regulator)
    |
    dordaviprone (ONC201) • TLY012